Elanix Biotechnologies AG operates as a holding company, which engages in the development and marketing of progenitor cell-based products for acute wound care, as well as dermatological and gynecological applications. It operates through the Regenerative Medicine and Cosmetic Ointments business segments. The Regenerative Medicine segment offers skin dressings made from progenitor skin fibroblasts to provide protection and accelerated healing for burns and reconstructive surgery. The Cosmetic Ointments segment develops and markets creams for soothing discomfort, enhancing the feeling of softness, and protection against external aggressions in gynecological applications, as well as for accelerated skin healing. The company was founded by Lee-Ann Applegate, Wassim Raffoul, Anthony De Buys Roessingh, Nathalie Hirt-Burri, and Corinne Scaletta in 2013 and is headquartered in Wiesbaden, Germany.